Advertisement
Screener

AETHLON MEDICAL, INC. (AEMD) Scorecard

2.8 / 5 stars · 68/120 Roast Me

AETHLON MEDICAL, INC. (AEMD) Scorecard

  • 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
  • 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
  • 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
  • 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
32/120 All 120 Win/Lose results shown below

Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.

Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026

Complete point ledger

Each cell identifies the missing side explicitly.

QuarterTotal returnRevenue growthEPS growth
2026-Q20/3 LoseAEMD / S&P
-62.56% / 15.20%
LoseAEMD / S&P
AEMD unavailable / 15.00%
LoseAEMD / S&P
-90.75% / 50.40%
2026-Q10/3 LoseAEMD / S&P
-20.94% / -4.33%
LoseAEMD / S&P
AEMD unavailable / 11.30%
LoseAEMD / S&P
-27.33% / 27.70%
2025-Q41/3 LoseAEMD / S&P
-63.07% / 2.65%
LoseAEMD / S&P
AEMD unavailable / 9.00%
WinAEMD / S&P
34.76% / 13.40%
2025-Q31/3 LoseAEMD / S&P
-37.50% / 8.12%
LoseAEMD / S&P
AEMD unavailable / 4.61%
WinAEMD / S&P
69.74% / 13.45%
2025-Q21/3 LoseAEMD / S&P
-58.33% / 10.94%
LoseAEMD / S&P
AEMD unavailable / 4.83%
WinAEMD / S&P
163.22% / 10.63%
2025-Q11/3 LoseAEMD / S&P
-58.14% / -4.27%
LoseAEMD / S&P
AEMD unavailable / 4.98%
WinAEMD / S&P
70.72% / 10.57%
2024-Q42/3 WinAEMD / S&P
82.98% / 2.41%
LoseAEMD / S&P
AEMD unavailable / 5.25%
WinAEMD / S&P
1187.10% / 6.15%
2024-Q31/3 LoseAEMD / S&P
-6.00% / 5.89%
LoseAEMD / S&P
AEMD unavailable / 5.89%
WinAEMD / S&P
1042.03% / 6.11%
2024-Q21/3 LoseAEMD / S&P
-70.24% / 4.28%
LoseAEMD / S&P
AEMD unavailable / 5.38%
WinAEMD / S&P
638.90% / 5.12%
2024-Q11/3 LoseAEMD / S&P
-23.29% / 10.56%
LoseAEMD / S&P
AEMD unavailable / 5.71%
WinAEMD / S&P
805.83% / 5.59%
2023-Q41/3 LoseAEMD / S&P
-4.78% / 11.69%
LoseAEMD / S&P
AEMD unavailable / 6.81%
WinAEMD / S&P
40.91% / 7.78%
2023-Q31/3 LoseAEMD / S&P
-36.11% / -3.27%
LoseAEMD / S&P
AEMD unavailable / 7.52%
WinAEMD / S&P
97.95% / -5.03%
2023-Q21/3 LoseAEMD / S&P
-5.26% / 8.74%
LoseAEMD / S&P
AEMD unavailable / 9.50%
WinAEMD / S&P
646.58% / -8.57%
2023-Q13/3 WinAEMD / S&P
35.71% / 7.50%
WinAEMD / S&P
95.21% / 10.77%
WinAEMD / S&P
512.86% / -15.69%
2022-Q40/3 LoseAEMD / S&P
-51.72% / 7.56%
LoseAEMD / S&P
-95.84% / 11.88%
LoseAEMD / S&P
AEMD unavailable / -17.99%
2022-Q30/3 LoseAEMD / S&P
-48.21% / -4.88%
LoseAEMD / S&P
-96.72% / 13.47%
LoseAEMD / S&P
AEMD unavailable / -1.41%
2022-Q20/3 LoseAEMD / S&P
-23.29% / -16.10%
LoseAEMD / S&P
-79.50% / 13.71%
LoseAEMD / S&P
AEMD unavailable / 11.04%
2022-Q10/3 LoseAEMD / S&P
-21.51% / -4.60%
LoseAEMD / S&P
-55.37% / 15.97%
LoseAEMD / S&P
AEMD unavailable / 42.23%
2021-Q40/3 LoseAEMD / S&P
-51.81% / 11.03%
LoseAEMD / S&P
-62.09% / 15.00%
LoseAEMD / S&P
AEMD unavailable / 96.40%
2021-Q31/3 LoseAEMD / S&P
-21.54% / 0.58%
WinAEMD / S&P
48.83% / 10.77%
LoseAEMD / S&P
AEMD unavailable / 69.42%
2021-Q22/3 WinAEMD / S&P
142.36% / 8.55%
WinAEMD / S&P
27.55% / 6.58%
LoseAEMD / S&P
AEMD unavailable / 51.81%
2021-Q11/3 LoseAEMD / S&P
-17.81% / 6.17%
WinAEMD / S&P
1.37% / -1.06%
LoseAEMD / S&P
AEMD unavailable / 7.39%
2020-Q42/3 WinAEMD / S&P
82.96% / 12.15%
WinAEMD / S&P
58.87% / -3.72%
LoseAEMD / S&P
AEMD unavailable / -33.42%
2020-Q31/3 LoseAEMD / S&P
-33.50% / 8.93%
WinAEMD / S&P
463.81% / -2.04%
LoseAEMD / S&P
AEMD unavailable / -27.10%
2020-Q22/3 WinAEMD / S&P
33.55% / 20.54%
WinAEMD / S&P
463.81% / -0.46%
LoseAEMD / S&P
AEMD unavailable / -27.11%
2020-Q12/3 WinAEMD / S&P
58.33% / -19.60%
WinAEMD / S&P
183.15% / 3.47%
LoseAEMD / S&P
AEMD unavailable / -14.75%
2019-Q41/3 LoseAEMD / S&P
-72.17% / 9.07%
WinAEMD / S&P
133.23% / 5.36%
LoseAEMD / S&P
AEMD unavailable / 2.99%
2019-Q30/3 LoseAEMD / S&P
-37.84% / 1.70%
LoseAEMD / S&P
-63.24% / 5.02%
LoseAEMD / S&P
AEMD unavailable / 0.21%
2019-Q20/3 LoseAEMD / S&P
-61.05% / 4.30%
LoseAEMD / S&P
-63.24% / 6.64%
LoseAEMD / S&P
AEMD unavailable / 8.65%
2019-Q11/3 LoseAEMD / S&P
-42.77% / 13.65%
WinAEMD / S&P
53.47% / 8.12%
LoseAEMD / S&P
AEMD unavailable / 14.29%
2018-Q42/3 WinAEMD / S&P
40.68% / -13.52%
WinAEMD / S&P
200.00% / 9.05%
LoseAEMD / S&P
AEMD unavailable / 18.23%
2018-Q30/3 LoseAEMD / S&P
-7.81% / 7.71%
LoseAEMD / S&P
AEMD unavailable / 10.21%
LoseAEMD / S&P
AEMD unavailable / 19.06%
2018-Q21/3 WinAEMD / S&P
7.56% / 3.43%
LoseAEMD / S&P
AEMD unavailable / 9.03%
LoseAEMD / S&P
AEMD unavailable / 14.46%
2018-Q11/3 WinAEMD / S&P
5.31% / -0.76%
LoseAEMD / S&P
AEMD unavailable / 7.68%
LoseAEMD / S&P
AEMD unavailable / 12.46%
2017-Q40/3 LoseAEMD / S&P
-26.62% / 6.64%
LoseAEMD / S&P
AEMD unavailable / 7.03%
LoseAEMD / S&P
AEMD unavailable / 13.82%
2017-Q30/3 LoseAEMD / S&P
-28.04% / 4.48%
LoseAEMD / S&P
AEMD unavailable / 5.68%
LoseAEMD / S&P
AEMD unavailable / 17.57%
2017-Q20/3 LoseAEMD / S&P
-34.56% / 3.09%
LoseAEMD / S&P
AEMD unavailable / 4.83%
LoseAEMD / S&P
AEMD unavailable / 17.74%
2017-Q10/3 LoseAEMD / S&P
-22.14% / 6.07%
LoseAEMD / S&P
AEMD unavailable / 3.67%
LoseAEMD / S&P
AEMD unavailable / 13.32%
2016-Q40/3 LoseAEMD / S&P
-16.33% / 3.82%
LoseAEMD / S&P
AEMD unavailable / 2.09%
LoseAEMD / S&P
AEMD unavailable / 7.05%
2016-Q30/3 LoseAEMD / S&P
-11.93% / 3.85%
LoseAEMD / S&P
AEMD unavailable / 0.20%
LoseAEMD / S&P
AEMD unavailable / -3.15%

Dividend-reinvested, split-adjusted total return

1Y · 2025-08-29 to 2026-08-27

MetricAEMD total returnS&P 500 Total Return Index
Total return-88.40%20.78%
Annualized return-88.40%20.78%

5Y · 2021-09-01 to 2026-08-27

MetricAEMD total returnS&P 500 Total Return Index
Total return-99.93%83.14%
Annualized return-76.41%12.86%

10Y · 2016-09-01 to 2026-08-27

MetricAEMD total returnS&P 500 Total Return Index
Total return-100.00%319.30%
Annualized return-64.17%15.41%

Calculation rules

window
Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
return Basis
Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
point Rule
Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
frequency
Quarter endpoints only.
fundamentals
Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
non Scoring

Snapshot captured 2026-09-04.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Bluejay Diagnostics, Inc. (BJDX)United States$0.004B
INTELLIGENT BIO SOLUTIONS INC. (INBS)United States$0.005B
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Autonomix Medical, Inc. (AMIX)United States$0.004B
Sonoma Pharmaceuticals, Inc. (SNOA)United States$0.006B-2.59
enVVeno Medical Corp (NVNO)United States$0.006B-0.48
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
Vivos Therapeutics, Inc. (VVOS)United States$0.003B-0.26
Co-Diagnostics, Inc. (CODX)United States$0.007B-0.32